- Trials with a EudraCT protocol (341)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
341 result(s) found for: Viruses.
Displaying page 1 of 18.
EudraCT Number: 2017-000848-17 | Sponsor Protocol Number: MI-CP129 | Start Date*: 2017-12-12 |
Sponsor Name:MedImmune | ||
Full Title: A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to less than 60 Months of Age | ||
Medical condition: The prevention of Influenza Virus in infants and young children ages 6 to < 60 months of age. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-004248-11 | Sponsor Protocol Number: Ahus-ATHENIAN | Start Date*: 2021-11-10 |
Sponsor Name:Akershus University Hospital | ||
Full Title: Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult pat... | ||
Medical condition: Patients with viral respiratory tract infection (influenza virus, parainfluenza virus, respiratory syncytial virus or human metapneumovirus) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003868-25 | Sponsor Protocol Number: DEN-03-IB | Start Date*: 2024-04-22 | |||||||||||
Sponsor Name:Instituto Butantan | |||||||||||||
Full Title: Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Dengue 1,2,3,4 (Attenuated) Vaccine produced by Instituto Butantan | |||||||||||||
Medical condition: Dengue | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022110-29 | Sponsor Protocol Number: SG006 | Start Date*: 2010-10-08 |
Sponsor Name:Synairgen Research Limited | ||
Full Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral in... | ||
Medical condition: Prevention or attenuation of COPD symptoms caused by respiratory viruses | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004817-98 | Sponsor Protocol Number: Tri-VSTs | Start Date*: 2019-06-25 |
Sponsor Name:Ελληνική Αιματολογική Εταιρεία | ||
Full Title: Administration of Rapidly Generated Multivirus-Specific Cytotoxic TLymphocytes for the Treatment of CMV, EBV, and BK virus Infections post Allogeneic Stem Cell Transplant | ||
Medical condition: Infections from EBV, CMV and BK virus post allogeneic Stem Cell Transplant | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002096-34 | Sponsor Protocol Number: AER-2012 | Start Date*: 2012-10-29 | |||||||||||
Sponsor Name:Crucell Holland B.V. | |||||||||||||
Full Title: Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur® | |||||||||||||
Medical condition: healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020371-22 | Sponsor Protocol Number: UMCN-AKF 10.04 | Start Date*: 2011-05-03 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: Achieving appropriate exposuRe to RIBAvirin after a dose advise based on an abbreviated AUC of a first dose of ribavirin (ARRIBA) | |||||||||||||
Medical condition: chronic HCV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000492-32 | Sponsor Protocol Number: T16/2013 | Start Date*: 2013-07-10 |
Sponsor Name:Turku University Hospital | ||
Full Title: T cell and interferon expression in tonsils after sublingual immunotherapy and/or nasal live attenuated influenza vaccine | ||
Medical condition: We investigate the effects of allergen and virus on patients with recurrent tonsillitis or tonsillar hypertrphy. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004905-26 | Sponsor Protocol Number: 115649 | Start Date*: 2012-10-10 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: Immunogenicity and safety study of GSK Biologicals’ Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s MMR vaccine when both are given on a 2-dose schedule to... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FI (Completed) CZ (Completed) ES (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005825-75 | Sponsor Protocol Number: 105909 MeMuRu-OKA 047 | Start Date*: 2006-03-20 | |||||||||||
Sponsor Name:GLAXO SMITHKLINE | |||||||||||||
Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and ... | |||||||||||||
Medical condition: Active immunisation against mumps, measles, rubella and varicella | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005500-14 | Sponsor Protocol Number: MZ-ATRACTION/ML 20804 | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:Universitätsmedizin der Johannes-Gutenberg Universität Mainz | |||||||||||||
Full Title: A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGA... | |||||||||||||
Medical condition: chronic HCV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002669-19 | Sponsor Protocol Number: X04-VAR-402 | Start Date*: 2004-12-23 | |||||||||||
Sponsor Name:AVENTIS PASTEUR MSD S.P.A. | |||||||||||||
Full Title: A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants. | |||||||||||||
Medical condition: Active immunisation against varicella | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017480-42 | Sponsor Protocol Number: SG005 | Start Date*: 2010-03-03 |
Sponsor Name:Synairgen Research Ltd | ||
Full Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory vir... | ||
Medical condition: prevention or attenuation of asthma symptoms caused by respiratory viruses | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002014-39 | Sponsor Protocol Number: RTB-101-205 | Start Date*: 2019-08-30 |
Sponsor Name:resTORbio, Inc. | ||
Full Title: A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly | ||
Medical condition: Clinically Symptomatic Respiratory Illness in the Elderly | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012579-90 | Sponsor Protocol Number: 1220.40 | Start Date*: 2009-08-04 | |||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||||||||||||
Full Title: Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and... | |||||||||||||||||||||||
Medical condition: chronic hepatitis C | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004891-12 | Sponsor Protocol Number: 115648 | Start Date*: 2012-11-02 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: EE (Completed) FI (Completed) ES (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012876-29 | Sponsor Protocol Number: 10762 | Start Date*: 2009-07-07 |
Sponsor Name:University Hospitals Leicester | ||
Full Title: A prospective study to assess emergence and transmissibility of drug resistance to neuraminidase inhibitor following treatment of children and adults with acute pandemic influenza | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014637-24 | Sponsor Protocol Number: ID-INT/09 | Start Date*: 2009-09-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA | |||||||||||||
Full Title: On field immunization with a novel influenza vaccine administered via intradermic route (Intanza): tolerability, safety, immunogenicity and acceptability study in subjects ≥ 60 years and evaluation... | |||||||||||||
Medical condition: patients withAge >= 60 years | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003886-17 | Sponsor Protocol Number: NL21828 | Start Date*: 2008-12-08 |
Sponsor Name:VieCuri Medisch Centrum voor Noord-Limburg | ||
Full Title: Effect of inhaled hypertonic saline solution to treat infants hospitalized with viral bronchiolitis. | ||
Medical condition: Acute viral bronchiolitis (an infection of the lower airways) in infants under two years of age. This is usually caused by Respiratory Syncytial Virus (RSV). The diagnosis of viral bronchiolitis wi... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002685-12 | Sponsor Protocol Number: Treg002 | Start Date*: 2013-05-22 | |||||||||||
Sponsor Name:University Hospital Regensburg | |||||||||||||
Full Title: Treatment of steroid resistant severe acute gastrointestinal graft-versus-host disease with in vitro expanded donor-derived regulatory T cells A prospective open-label one-armed non-randomized mul... | |||||||||||||
Medical condition: Steroid resistant severe acute gastrointestinal graft-versus-host disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
